Trade Names:Adoxa- Tablets 50 mg (as monohydrate)- Tablets 75 mg (as monohydrate)- Tablets 100 mg (as monohydrate)
Trade Names:Atridox- Injection 42.5 mg (as hyclate, 10%)
Trade Names:Doryx- Capsules, coated pellets 75 mg (as hyclate)- Capsules, coated pellets 100 mg (as hyclate)- Capsules, coated pellets 150 mg (as hyclate)
Trade Names:Doxy 100- Powder for Injection, lyophilized 100 mg (as hyclate)
Trade Names:Doxy 200- Powder for Injection, lyophilized 200 mg (as hyclate)
Trade Names:Monodox- Capsules 50 mg (as monohydrate)- Capsules 100 mg (as monohydrate)
Trade Names:NutriDox- Capsules 75 mg (as monohydrate)
Trade Names:Oracea- Capsules 40 mg
Trade Names:Periostat- Tablets 20 mg (as hyclate)
Trade Names:Vibramycin- Capsules 100 mg (as hyclate)- Powder for Injection 100 mg (as hyclate)- Powder for Oral Suspension 25 mg (as monohydrate) per 5 mL when reconstituted- Syrup 50 mg per 5 mL (as calcium)
Trade Names:Vibra-Tabs- Tablets 100 mg (as hyclate)Apo-Doxy (Canada)Apo-Doxy-Tabs (Canada)Doxycin (Canada)Nu-Doxycycline (Canada)
Inhibits bacterial protein synthesis.
Well absorbed. T max is 2 to 2.6 h (oral). C max is 2.6 mcg/mL (200 mg oral hyclate dose), 2.5 to 3.6 mcg/mL (100 to 200 mg IV dose). Absorption may be decreased by 20% when given with food or milk.
Bound to plasma proteins. Crosses the placenta; excreted in breast milk.
Approximately 40% excreted by the kidneys in 72 h. The t ½ is 16 to 22 h.
Excretion by the kidneys may fall as low as 1% to 5% in 72 h in those with Ccr less than 10 mL/min.
Treatment of infections caused by susceptible strains of gram-positive and gram-negative bacteria (eg, Rickettsia , Mycoplasma pneumoniae ); treatment of trachoma and susceptible infections when penicillins are contraindicated; treatment of acute intestinal amebiasis; uncomplicated gonorrhea in adults; prophylaxis of malaria caused by Plasmodium falciparum ; anthrax (including inhalational anthrax); severe acne; treatment of only inflammatory lesions of rosacea ( Oracea only).Periodontitis Tablet
Adjunct treatment to scaling and root planing to promote attachment level gain and reduce pocket depth.Subgingival injection
For chronic adult periodontitis for a gain in clinical attachment, reduction in probing depth, and reduction in bleeding on probing.
Hypersensitivity to tetracyclines; nursing mothers, infants, and children ( Periostat ).
PO 100 mg twice daily for at least 10 days.Chlamydia InfectionsAdults and Children 8 yr of age and older
PO 100 mg twice daily for 7 days.Epididymitis Most Likely Caused by Gonococcal or Chlamydial InfectionAdults
PO 100 mg twice daily for 10 days plus a single dose of 250 mg ceftriaxone IM.InfectionAdults and children older than 8 yr of age and weighing more than 45 kg
PO 200 mg on the first day (100 mg every 12 h) then 100 mg/day. For more severe infections (particularly chronic UTI), administer 100 mg every 12 h. In streptococcal infections, continue therapy for 10 days. IV 200 mg on the first day (as 1 or 2 infusions) then 100 to 200 mg/day, depending upon the severity of infections, with 200 mg administered in 1 or 2 infusions.Children older than 8 yr of age and weighing 45 kg or less
PO 4.4 mg/kg divided into 2 doses on day 1 followed by 2.2 mg/kg/day as a single dose or divided into 2 doses on subsequent day. For more severe infections, 4.4 mg/kg may be used. In streptococcal infections, continue therapy for 10 days. IV 4.4 mg/kg on day 1 (in 1 or 2 infusions) followed with 2.2 to 4.4 mg/kg given as 1 or 2 infusions, depending on the severity of the infection.Lymphogranuloma Venereum and Granuloma InguinaleAdults
PO 100 mg twice daily for at least 21 days.Malaria ProphylaxisAdults
PO 100 mg daily, beginning 1 to 2 days before travel and continuing for 4 wk after leaving area.Children older than 8 yr of age
PO 2 mg/kg daily up to 100 mg per day. Begin 1 to 2 days before travel and continue for 4 wk after leaving area.Nongonococcal UrethritisAdults
PO 100 mg twice daily for 7 days.Pelvic Inflammatory DiseaseAdults
PO / IV 100 mg every 12 h plus 2 g cefotetan IV every 12 h or 2 g cefoxitin IV every 6 h. Parenteral therapy may be discontinued after 24 h; continue oral therapy with doxycycline for a total of 14 days.Periodontitis ( Periostat , Atridox )Adults
PO 20 mg twice daily as an adjunct following scaling and root planing for up to 9 mo. Administer tablets at least 2 h before or after meals.Adults
Subgingival Injection Variable dose, depending on the size, shape, and number of pockets being treated (see product information for preparation and administration).Rosacea ( Oracea )Adults
PO 40 mg in the morning on an empty stomach, at least 1 h prior to or 2 h after a meal.Sexual Assault ProphylaxisAdults
PO 100 mg twice daily for 7 days plus ceftriaxone and metronidazole.SyphilisEarly (except Adoxa , NutriDox , Monodox )
PO 100 mg twice daily for 14 days.More than 1 yr duration (except Adoxa , NutriDox , Monodox )
100 mg twice daily for 28 days.Primary and secondary ( Adoxa , NutriDox , Monodox )
300 mg/day in divided doses for at least 10 days.Uncomplicated Gonococcal Infection (Except Anorectal Infections in Men)Adults
PO 100 mg twice daily for at least 7 days. Single visit dose: 300 mg immediately followed with 300 mg in 1 h.Uncomplicated Urethral, Endocervical, or Rectal Infections Caused by C. TrachomatisAdults
PO 100 mg twice daily for at least 7 days.Inhalation Anthrax (Post-exposure)Adults and children (100 lb [45 kg] or more)
PO 100 mg twice daily for 60 days.Children (less than 100 lb [45 kg])
PO 2.2 mg/kg twice daily for 60 days.
Store tablets, capsules, syrup, and oral suspension at controlled room temperature (59° to 86°F). Solutions diluted with other IV infusion solutions may be stored for up to 72 h prior to start of infusion if refrigerated (36° to 46°F) and protected from sunlight and artificial light. Infusion must be completed within 12 h. Discard any remaining solution after 12 h. Store lyophilized powder at controlled room temperature at or below 77°F. Store unopened Atridox pouch in refrigerator (36° to 46°F). Pouch can be removed from refrigerator 15 min before mixing. Coupled syringes can be stored in the resealable pouch for up to 3 days at room temperature.
May decrease oral absorption of doxycycline.Barbiturates, carbamazepine, hydantoins
May increase metabolism of and decrease effect of doxycycline.Cholestyramine, colestipol
May decrease absorption of doxycycline.Digoxin
May increase digoxin serum levels.Iron salts
May decrease absorption of doxycycline.Isotretinoin
Because the risk of pseudotumor cerebri may be increased, avoid isotretinoin administration shortly before, during, or after doxycycline therapy.Methoxyflurane
Increased potential for nephrotoxicity exists; do not use together.Milk and dairy products
Although the effects of milk and dairy products on doxycycline absorption are less than observed with other tetracycline derivatives, avoid the administration of milk or dairy products with all tetracycline derivatives.Oral contraceptives
May decrease contraceptive efficacy.Penicillins
May interfere with bactericidal action of penicillins.Warfarin
Anticoagulant effect may be increased; dose may need to be decreased.
False elevations of urinary catecholamine levels may occur because of interference with fluorescence test.
Dizziness; headache; pseudotumor cerebri (manifested by headache and blurred vision).
Maculopapular and erythematous rashes; exfoliative dermatitis; photosensitivity.
Anorexia; nausea; vomiting; diarrhea; glossitis; dysphagia; enterocolitis; inflammatory lesions (with monilial overgrowth) in anogenital area; abdominal pain or discomfort; bulky loose stools; sore throat.
Hemolytic anemia; thrombocytopenia; neutropenia; eosinophilia.
Hypersensitivity (including urticaria, angioneurotic edema, anaphylaxis, anaphylactoid reactions, purpura, pericarditis, exacerbation of SLE).
Bulging fontanels (infants); benign intracranial hypertension (adults).
Review results of culture and sensitivity testing as appropriate. Ensure that CBC, liver enzymes, and renal function are periodically evaluated during prolonged therapy.
Category D .
Excreted in breast milk.
Not recommended in children younger than 8 yr of age; abnormal bone formation and tooth discoloration may result; not recommended for use in children ( Oracea )
Dosage reduction may be required.
Doses greater than 2 g/day associated with liver failure; monitor function and avoid other hepatotoxic drugs.
Prolonged use may result in bacterial or fungal overgrowth.
Photosensitivity may occur; avoid exposure to sunlight or ultraviolet light.
Do not use; degradation products of drug are highly nephrotoxic.
May result in thrombophlebitis; use oral form whenever reasonable.
Doxycycline periodontal injection has not been clinically evaluated for use in the regeneration of alveolar bone, use in immunocompromised patients, or for use in patients with conditions involving extremely severe periodontal defects with very little remaining periodontium.
Copyright © 2009 Wolters Kluwer Health.